Divi's Laboratories jumped 6.25% to Rs 2,094.45 at 10:09 IST on BSE after net profit rose 45% to Rs 243 crore on 26% growth in total income to Rs 809 crore in Q1 June 2015 over Q1 June 2014.
The Q1 result was announced on Saturday, 8 August 2015.
Meanwhile, the S&P BSE Sensex was up 140.54 points or 0.5% at 28,376.93.
On BSE, so far 36,000 shares were traded in the counter as against average daily volume of 12,826 shares in the past one quarter.
The stock hit a high of Rs 2,129.90 so far during the day, which is a record high for the counter. The stock hit a low of Rs 2,070.15 so far during the day. The stock had hit a 52-week low of Rs 1,449 on 12 August 2014.
The stock had outperformed the market over the past one month till 7 August 2015, advancing 3.43% compared with Sensex's 0.23% rise. The scrip had also outperformed the market in past one quarter, surging 14.26% as against Sensex's 6.16% rise.
The large-cap pharma company has equity capital of Rs 26.55 crore. Face value per share is Rs 2.
Divi's Laboratories reported a forex gain of Rs 21 crore in Q1 June 2015 as against a forex gain of Rs 1 crore in Q1 June 2014.
Divi's Laboratories' board of directors at its meeting held on Saturday, 8 August 2015, recommended 1:1 bonus issue of shares i.e. one equity share for every share held as on record date.
Divis Laboratories is primarily engaged in the manufacture of active pharmaceutical ingredients (APIs) & intermediates for generics, custom synthesis of API's and advanced intermediates for discovery compounds for pharma giants, building blocks for peptides, building blocks for nucleotides, carotenoids and chiral ligands.
Powered by Capital Market - Live News
